Animalcare Group Plc · LSE:ANCR
Animalcare — FY2020 Earnings Presentation
10 slides from Animalcare's earnings presentation, Mar 30, 2021
Slide 1: Full year results 2020
30 MARCH 2021 Full year results 2020 Jenny Winter, Chief Executive Officer Chris Brewster, Chief Financial Officer
Slide 2: Disclaimer
Disclaimer The information contained in this confidential document (“Presentation”) has been prepared by the Company. It has not been verified by the Company and is subject to material updating, revision and further amendment. This Presentation has not been approved by an authorised person in accord
Slide 3: Strategic progress in extraordinarily challenging year
Strategic progress in extraordinarily challenging year Strong Financial sustainability through revenue growth, cash ! Cash conversion 102.9% 2020 finances conversion, EPS growth and EBITDA margin growth ! Net debt further reduced to £13.6m Key Organisation for success; leadership strength and core !
Slide 4: Financial highlights 2020
Financial highlights 2020 Revenue Underlying* EBITDA £70.5m £12.1m 2019 2019 £71.1m £13.1m ↓0.9% ↓8.0% 2020 2020 £70.5m £12.1m Down 2.0% at CER Underlying EBITDA margin 17.2%; 18.5% for prior year Underlying cash Net debt conversion 2019 £13.6m 2019 118.4% £17.8m ↓102.9% 102.9% ↓£4.2m 2020 2020 £13.
Slide 5: Variable market dynamics during 2020
Variable market dynamics during 2020 2020 revenue % by country % change 2020 revenue % change by segment v 2019 26% Spain ↓3% Equine & other Production 16% UK ↓15% ↑2.6% ↑4.6% Animals 15% Germany ↑4% 86% 12% Benelux ↓11% H1 2020 £70.4m of revenues from 11% Italy ↑31% Companion own operations ↓2% Ani
Slide 6: Financial platform enables growth strategy
Financial platform enables growth strategy Strengthening balance sheet provides capacity for investment LEADERSHIP GROWTH STEM BIOFILMS CHANGE STRATEGY DEAL PORTFOLIO DAXOCOX OPTIMISATION LAUNCH* 2017 2018 2019 2020 2021 £25.9m NET DEBT REDUCED BY £23.7m £23.6m NEARLY 50% FROM PEAK 2.2x 2.0x £17.8m
Slide 7: Advancing leadership agenda
Advancing leadership agenda ↑11% • Double-digit • Upper percentile rank • Increased improvement in of the Gallup Q12 participation – 89% of employee participants database employee population engagement GALLUP • New organisation • Increased focus/ • Streamlined, highly structure accountability on exp
Slide 8: Improving quality and shape of portfolio
Improving quality and shape of portfolio ↑3.2% YOY Smaller number of higher selling, higher margin products increases management focus and impact of sales and marketing activity 2020 At merger 71% 63% of revenues of revenues 14% of revenues generated by smallest 236 brands from top 40 from top 40 se
Slide 9: Pipeline and business development delivering
Pipeline and business development delivering Daxocox • EU Marketing authorisation expected mid-April • Launch planned early in second half 2021 • Extend geographic reach through partnerships • Daxocox a new addition to fast-growing mixed chronic/acute pain market: £130m segment in Europe alone R&D i
Slide 10: Summary and outlook
Summary and outlook Summary • Resilient performance in face of pandemic • Strong cash generation • Continuing reduction in net debt • Increased capacity to invest in growth • Strategic and operational progress on all fronts • Pipeline and business development delivering Outlook • Encouraging Q1 reve